publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
system
vaccinolog
identifi
earli
innat
immun
signatur
correl
antibodi
respons
ebola
vaccin
rvsvzebov
graphic
abstract
highlight
earli
innat
marker
correl
antibodi
respons
ebola
vaccin
rvsvzebov
day
vaccin
independ
correl
antibodi
induct
rnaseq
analysi
identifi
earli
gene
express
signatur
link
recent
outbreak
emerg
infect
caus
virus
ebola
middl
east
respiratori
syndrom
mer
coronaviru
zika
viru
repres
global
threat
emphas
critic
need
new
vaccin
concept
vector
rapid
clinic
develop
howev
predict
achiev
vaccin
efficaci
remain
major
challeng
acceler
vaccin
develop
system
vaccinolog
approach
assist
identif
earli
immun
signatur
predict
vaccin
immunogen
pulendran
et
al
previou
studi
investig
potenti
earli
innat
immun
signatur
predict
antibodi
respons
vaccin
yellow
fever
influenza
vaccin
nakaya
et
al
querec
et
al
gaucher
et
al
furman
et
al
among
other
li
et
al
remain
unknown
whether
molecular
signatur
identifi
use
predict
immun
respons
novel
vaccin
appli
system
vaccinolog
approach
disentangl
earli
innat
immun
respons
elicit
ebola
vaccin
rvsvzair
ebola
viru
zebov
identifi
innat
immun
respons
correl
ebola
viru
ebov
glycoprotein
gp
specif
antibodi
induct
replicationcompet
recombin
vaccin
candid
base
vesicular
stomat
viru
rvsv
base
vaccin
vector
limit
data
immun
respons
innat
immun
profil
human
report
thu
far
rvsvzebov
repres
one
promis
ebola
vaccin
candid
date
anticip
licensur
expect
soon
vaccin
shown
protect
relev
ebov
anim
challeng
model
includ
nonhuman
primat
nhp
confer
protect
jone
et
al
qiu
et
al
geisbert
et
al
geisbert
et
al
furthermor
ebov
candid
vaccin
efficaci
evalu
risk
infect
human
possibl
clusterrandom
ring
vaccin
trial
conduct
guinea
show
promis
result
demonstr
strategi
contact
trace
immedi
ring
vaccin
contact
rvsvzebov
vaccin
protect
ebola
viru
diseas
compar
control
henaorestrepo
et
al
ring
vaccin
trial
focus
clinic
endpoint
assess
immun
respons
induc
vaccin
safeti
immunogen
vaccin
rvsvzebov
evalu
number
investigatoriniti
doseescal
phase
clinic
trial
coordin
world
health
organ
led
african
european
vsvebola
consortium
vebcon
inform
dose
select
efficaci
trial
harmon
independ
investigatoriniti
phase
trial
complet
took
place
four
differ
intern
site
includ
univers
medic
center
hamburgeppendorf
uke
germani
agnandji
et
al
trial
vaccin
rvsvzebov
shown
immunogen
induc
gpspecif
antibodi
particip
agnandji
et
al
howev
immunolog
mechan
lead
antibodi
induct
particular
role
earli
innat
immun
respons
vaccin
vector
remain
elucid
system
vaccinolog
approach
present
comprehens
dissect
innat
immun
profil
rvsvzebov
reveal
strong
earli
innat
immun
activ
follow
vaccin
subset
earli
innat
marker
encompass
interferonginduc
protein
subset
monocyt
dendrit
cell
natur
killer
nk
cell
well
earli
gene
signatur
link
pathway
identifi
innat
immun
signatur
correl
gpspecif
antibodi
respons
day
beyond
human
data
recombin
vsv
vaccin
platform
scarc
studi
make
import
contribut
understand
immunolog
properti
vaccin
human
may
provid
uniqu
insight
futur
use
vector
technolog
emerg
vaccin
includ
candid
vaccin
current
develop
zika
viru
betancourt
et
al
human
data
immun
induc
vaccin
base
rvsv
vector
scarc
therefor
first
studi
earli
plasma
cytokin
respons
induc
vaccin
plasma
isol
day
vaccin
analyz
concentr
level
receptor
antagonist
interferong
ifng
ifna
tumor
necrosi
factor
alpha
tnfa
tnfb
macrophageinflammatori
monocytechemoattract
use
luminex
assay
respect
cytokin
select
base
report
role
orchestr
host
immun
respons
vaccin
querec
et
al
nakaya
et
al
barouch
et
al
teigler
et
al
vaccin
rvsvzebov
induc
rapid
robust
increas
cytokin
level
maximum
peak
earli
day
signific
increas
concentr
level
note
day
day
rel
express
day
wilcoxon
signedrank
test
fals
discoveri
rate
fdr
adjust
p
cytokin
figur
cytokin
level
vaccin
dosedepend
highest
level
observ
higher
vaccin
dose
group
receiv
plaqueform
unit
pfu
compar
lower
dose
group
receiv
pfu
wilcoxon
ranksum
test
betweengroup
comparison
day
fdradjust
p
respect
figur
remain
cytokin
concentr
level
rang
standard
curv
measur
sever
time
point
statist
analys
perform
cytokin
altogeth
show
rvsvzebov
lead
signific
earli
induct
cytokin
maximum
plasma
peak
level
day
vaccin
rvsvzebov
vaccin
induc
expans
activ
innat
cell
subset
increas
express
innat
immun
marker
gain
addit
insight
underli
innat
immun
respons
rvsvzebov
vaccin
analyz
peripher
blood
mononuclear
cell
pbmc
chang
frequenc
activ
statu
innat
immun
cell
subset
includ
myeloid
plasmacytoid
dendrit
cell
mdc
pdc
respect
monocyt
nk
cell
vaccin
rvsvzebov
led
strong
earli
induct
wide
spectrum
activ
molecul
upregul
costimulatori
molecul
antigenpres
cell
monocyt
dc
nk
cell
figur
signific
modul
seen
frequenc
mdc
pdc
well
inflammatori
monocyt
accompani
increas
mean
fluoresc
intens
mfi
pdc
mdc
analysi
also
reveal
signific
upregul
sever
activ
marker
nk
cell
includ
figur
entir
spectrum
assess
innat
surfac
marker
shown
tabl
kinet
surfac
marker
express
frequenc
differ
among
distinct
cell
subset
peak
valu
either
reach
day
day
follow
vaccin
tabl
marker
frequenc
surfac
express
declin
follow
day
vaccin
figur
tabl
overal
rvsvzebov
vaccin
result
signific
earli
activ
nk
cell
inflammatori
monocyt
dc
day
day
vaccin
ebovgpbind
antibodi
respons
induc
vaccin
gpspecif
antibodi
respons
measur
use
elisa
two
central
laboratori
marburg
germani
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
usa
day
ebovgpbind
antibodi
measur
use
elisa
homolog
gp
zairekikwit
strain
short
kikwitgpspecif
antibodi
usamriid
day
day
time
point
avail
time
analysi
inactiv
whole
virion
zaireguecked
strain
short
gueckedougpspecif
antibodi
marburg
avail
time
point
day
agnandji
et
al
day
vaccin
rvsvzebov
vaccin
induc
glycoproteinspecif
antibodi
particip
dose
demonstr
robust
immunogen
figur
level
ebovgpbind
antibodi
durabl
time
day
figur
publish
previous
agnandji
et
al
respons
correl
later
ebovgp
antibodi
respons
use
multidimension
statist
approach
next
studi
whether
cytokin
andor
cell
surfac
marker
measur
day
vaccin
b
c
figur
strong
increas
cytokin
level
earli
day
vaccin
graph
show
box
whisker
plot
minimum
first
quartil
median
third
quartil
maximum
cytokin
level
differ
day
twosid
wilcoxon
signedrank
test
perform
withingroup
comparison
postvaccin
time
point
baselin
across
dose
group
n
trial
particip
signific
p
valu
adjust
multipl
test
adapt
fdr
shown
day
day
day
day
comparison
b
heatmap
reflect
plasma
concentr
cytokin
day
vaccin
dose
group
group
n
trial
particip
pfu
orang
symbol
group
n
trial
particip
pfu
blue
symbol
top
part
figur
gener
heatmap
plasma
concentr
level
rang
standard
curv
replac
valu
pgml
valu
per
cytokin
standard
c
box
whisker
plot
minimum
first
quartil
median
third
quartil
maximum
cytokin
level
dose
group
day
n
particip
per
dose
group
twosid
wilcoxon
ranksum
test
perform
betweengroup
comparison
p
valu
adjust
multipl
test
adapt
fdr
data
gener
one
experi
sampl
measur
duplic
combin
thereof
repres
earli
innat
immun
signatur
associ
later
antibodi
respons
multidimension
statist
analysi
method
use
assess
earli
innat
immun
respons
day
day
correl
subsequ
ebovgpspecif
antibodi
respons
given
high
number
predictor
variabl
earli
innat
immun
marker
variabl
across
day
day
day
small
sampl
size
trial
particip
took
advantag
full
spectrum
antibodi
respons
measur
day
day
increas
amount
respons
inform
model
use
spars
partial
leastsquar
spl
crossvalid
downselect
result
singl
spl
compon
includ
five
earli
innat
marker
correl
later
antibodi
respons
varianc
five
antibodi
respons
measur
explain
tabl
correl
matrix
select
innat
marker
antibodi
respons
variabl
shown
figur
addit
numer
result
shown
tabl
correl
among
innat
marker
figur
plasma
level
day
frequenc
bright
nk
cell
day
mean
fluoresc
intens
dim
nk
cell
day
postvaccin
posit
correl
antibodi
respons
day
onward
antibodi
level
day
strongli
correl
two
innat
immun
respons
marker
relat
express
monocyt
day
neg
correl
antibodi
respons
absolut
number
marker
identifi
flow
cytometri
shown
tabl
taken
togeth
data
reveal
signatur
five
earli
innat
immun
marker
correl
gpspecif
vaccineinduc
antibodi
respons
day
beyond
disentangl
whether
effect
five
select
innat
marker
independ
use
multivari
linear
regress
stepwis
bottomup
variabl
select
start
five
innat
marker
identifi
spl
analysi
assess
independ
determin
gueckedougpspecif
antibodi
respons
day
immunogen
time
point
primari
interest
ongo
vaccin
trial
two
signific
independ
determin
retain
final
multivari
model
method
plasma
level
day
signific
posit
determin
day
antibodi
respons
per
pgml
increas
plasma
level
day
level
gueckedouspecif
antibodi
increas
log
optic
densiti
unit
second
twosid
wilcoxon
sign
ranktest
perform
withingroup
comparison
postvaccin
time
point
baselin
across
dose
group
n
trial
particip
signific
p
valu
adjust
multipl
test
adapt
fdr
shown
day
day
day
day
comparison
data
gener
one
experi
see
also
tabl
signific
posit
determin
mean
fluoresc
intens
dim
nk
cell
day
per
unit
increas
mfi
level
gueckedouspecif
antibodi
increas
log
optic
densiti
unit
although
predict
valu
model
imperfect
root
squar
residu
rsr
leaveoneout
sd
explain
variabl
antibodi
respons
measur
day
kikwit
gpspecif
antibodi
level
day
use
respons
variabl
instead
gueckedougpspecif
antibodi
plasma
day
signific
determin
final
model
increas
kikwit
gpspecif
antibodi
log
elisa
unitsml
per
pgml
increas
plasma
confid
interv
p
adjust
r
rsr
leaveoneout
sd
altogeth
final
multivari
linear
model
identifi
two
earli
innat
marker
posit
independ
associ
later
ebovgueckedougpspecif
antibodi
respons
particular
among
five
marker
earli
innat
signatur
identifi
spl
model
plasma
day
found
statist
signific
posit
determin
antibodi
respons
day
thu
independ
associ
day
antibodi
respons
level
regardless
level
four
earli
marker
nextgener
rna
sequenc
full
blood
show
differenti
gene
express
vaccin
next
sought
assess
whether
earli
vaccin
effect
also
identifi
gene
express
level
whole
blood
sampl
day
differenti
gene
express
day
baselin
investig
genewis
use
voomlimma
method
law
et
al
sequenc
gene
measur
identifi
proteincod
exclud
gene
low
express
level
mean
count
gene
includ
statist
analys
highest
number
differenti
express
gene
observ
day
vaccin
gene
significantli
differenti
express
compar
day
figur
larger
upthan
downregul
figur
analyz
differenti
express
day
dose
group
separ
dose
effect
appar
differenti
express
gene
lower
dose
group
higher
dose
group
figur
among
differenti
express
gene
day
overal
dose
group
combin
gene
largest
fold
chang
includ
gene
encod
tabl
canon
pathway
analys
includ
signific
gene
day
ingenu
pathway
analysi
softwar
top
enrich
pathway
includ
interferon
signal
pathway
pathway
pattern
recognit
receptor
recognit
bacteria
virus
inflammasom
pathway
upregul
figur
earli
gene
express
signatur
link
pathway
correl
later
gpspecif
antibodi
respons
vaccin
next
assess
whether
earli
gene
express
correl
later
antibodi
respons
could
identifi
use
unbias
approach
includ
gene
express
level
analyz
gene
gene
day
potenti
predictor
regardless
differenti
express
level
use
spl
downselect
earli
signatur
gene
correl
multivari
antibodi
respons
measur
day
day
bootstrap
method
use
addit
leaveoneout
crossvalid
avoid
overfit
model
leaveoneout
crossvalid
identifi
signatur
gene
express
compris
gene
singl
compon
correl
later
antibodi
respons
figur
two
gene
consist
often
select
use
bootstrap
method
gene
first
gene
tifa
trafinteract
protein
forkheadassoci
domain
day
relat
pathway
figur
second
gene
solut
carrier
famili
member
day
known
relat
pathway
two
gene
tifa
significantli
differenti
express
concern
time
point
compar
baselin
mean
express
fold
chang
multiplicityadjust
p
valu
figur
pathway
analys
base
extern
curat
databas
ingenu
pathway
analysi
next
assess
whether
correl
reflect
identifi
pathway
also
present
dataset
figur
show
correl
tifa
gene
express
day
repres
intermedi
gene
pathway
day
gene
express
day
plasma
cytokin
concentr
day
analys
identifi
expect
correl
tifa
pathway
dataset
suggest
main
pathway
activ
via
nuclear
factor
kb
nfkb
complex
strongest
posit
correl
tifa
respect
gene
repres
complex
differenti
gene
express
analys
gene
also
among
differenti
upregul
gene
indic
time
point
compar
baselin
recent
unpreced
outbreak
ebola
viru
diseas
evd
west
africa
led
evalu
vsvbase
ebola
vaccin
rvsvzebov
openlabel
dose
escal
singlecent
phase
trial
uke
vaccin
induc
ebovgpspecif
antibodi
trial
particip
document
immunogen
agnandji
et
al
despit
uncertainti
immun
respons
actual
serv
correl
protect
ebola
viru
diseas
initi
studi
suggest
gpspecif
antibodi
play
crucial
role
confer
protect
follow
vaccin
nhp
vaccin
guinea
pig
jone
et
al
bukreyev
et
al
wong
et
al
warfield
et
al
use
system
vaccinolog
approach
identifi
uniqu
earli
innat
immun
signatur
emerg
vaccin
fill
critic
knowledg
gap
facilit
strateg
design
futur
immunotherapeut
intervent
studi
appli
highthroughput
technolog
coupl
method
integr
data
analys
power
tool
investig
larg
spectrum
innat
cell
surfac
marker
cytokin
gene
express
determin
whether
earli
innat
immun
respons
serv
correl
antibodi
induct
respons
rvsvzebov
vaccin
longitudin
assess
earli
innat
immun
respons
show
strong
earli
activ
innat
immun
respons
earli
day
vaccin
significantli
induc
day
vaccin
dosedepend
peak
level
increas
matrix
show
posit
correl
correspond
antibodi
respons
blue
neg
correl
red
stronger
intens
color
stronger
correl
see
also
figur
tabl
tabl
level
vaccin
also
report
previou
studi
investig
immun
respons
yellow
fever
vaccin
querec
et
al
inactiv
trival
inactiv
influenza
vaccin
tiv
nakaya
et
al
howev
studi
includ
analysi
immun
chang
earli
day
report
peak
level
cytokin
level
day
follow
vaccin
therefor
remain
unclear
whether
true
peak
miss
inde
reach
later
time
point
studi
dynam
cytokin
express
may
depend
vaccin
vector
use
line
previou
result
aforement
vaccin
studi
also
observ
strong
increas
frequenc
inflammatori
monocyt
dc
monocyt
found
peak
express
reach
earli
day
studi
compar
day
report
yellow
fever
vaccin
querec
et
al
indic
dynam
surfac
marker
express
innat
immun
cell
may
inde
depend
specif
vaccin
test
chang
frequenc
express
activ
marker
antigenpres
cell
reveal
studi
report
particularli
chang
frequenc
phenotyp
nk
cell
follow
vaccin
rvsvzebov
human
describ
previou
vaccin
studi
data
thu
provid
insight
full
pictur
earli
vaccineinduc
key
mediat
involv
innat
immun
respons
vaccin
nk
cell
previous
suggest
critic
player
mediat
earli
protect
ebola
infect
nhp
marzi
et
al
show
vaccin
rvsvzebov
protect
macaqu
lethal
challeng
west
african
ebovmakona
strain
intriguingli
complet
partial
protect
achiev
singl
dose
given
late
day
challeng
respect
even
adapt
antibodi
respons
develop
marzi
et
al
thu
marzi
et
al
implic
role
nk
cell
confer
earlyinduc
protect
vaccin
cytokin
signatur
induc
vaccin
highli
suggest
nk
cell
activ
eventu
result
nk
cellmedi
kill
virusinfect
cell
find
suggest
vaccinationinduc
activ
nk
cell
could
contribut
control
ebov
replic
specif
antibodi
respons
develop
furthermor
nk
cell
also
implic
surviv
ebov
infect
show
decis
role
nk
cell
lethal
ebola
viru
infect
feldmann
et
al
warfield
et
al
present
studi
mfi
dim
nk
cell
frequenc
bright
nk
cell
identifi
posit
correl
gpspecif
antibodi
respons
support
role
nk
cell
shape
subsequ
adapt
immun
member
seventransmembran
domain
g
proteincoupl
chemokin
receptor
ckr
famili
shown
act
chemokinetraffick
molecul
indispens
persist
nk
cell
memori
hapten
virus
anim
model
shimaoka
et
al
paust
von
andrian
paust
et
al
futur
studi
explor
whether
marker
display
function
role
vaccineinduc
gener
antibodi
respons
although
day
day
frequenc
bright
nk
cell
day
show
posit
correl
antibodi
respons
antigenpres
cell
inflammatori
monocyt
mdc
express
activ
marker
show
neg
associ
costimulatori
molecul
provid
key
signal
requir
cell
activ
fanslow
et
al
lu
et
al
sansom
et
al
neg
effect
vaccineinduc
inflammatori
monocyt
cell
prolifer
antibodi
product
report
previous
mice
mitchel
et
al
vaccinationinduc
inflamm
although
necessari
effect
immun
also
gener
strong
counterregulatori
immun
respons
mediat
primarili
inflammatori
monocyt
suppress
cell
respons
demonstr
suppress
cell
help
eventu
led
reduc
antibodi
titer
vaccin
mice
implic
potenti
role
inhibit
monocytemedi
inhibitori
respons
effect
strategi
enhanc
vaccin
immun
dc
share
mani
featur
monocyt
antigenpres
cell
counterregulatori
effect
adapt
immun
respons
elicit
cell
may
also
arguabl
yet
demonstr
taken
togeth
data
suggest
activ
inflammatori
monocyt
neg
effect
gener
gpspecif
antibodi
respons
reflect
counterregulatori
suppress
effect
antigenpres
cell
develop
adapt
immun
respons
solubl
posit
correl
gpspecif
antibodi
respons
day
statist
independ
downselect
innat
immun
marker
one
potent
cytokin
secret
monocyt
dc
dufour
et
al
secret
cell
stimul
type
ii
ifn
strong
chemoattract
activ
cell
gener
amplifi
antitumor
immun
recruit
antigenspecif
cell
antigenpres
dc
drain
lymph
node
christensen
et
al
interestingli
studi
shown
link
model
tumor
antigen
increas
tumor
antigenspecif
cell
immun
respons
mice
enhanc
antigen
present
chemoattract
thu
enhanc
vaccin
potenc
kang
et
al
also
demonstr
set
dcbase
tumor
vaccin
modif
vaccin
addit
gener
tumor
antigenspecif
cell
stronger
antitumor
effect
vaccin
mice
compar
control
group
kang
et
al
kang
et
al
furthermor
nextgener
rna
sequenc
reveal
dosedepend
differenti
gene
express
day
vaccin
gene
encod
among
gene
largest
fold
chang
gene
signatur
identifi
rna
sequenc
correl
later
antibodi
respons
includ
tifa
day
relat
pathway
analysi
perform
unbias
way
influenc
result
marker
identifi
cytokinechemokin
flow
cytometri
analys
show
innat
signatur
correl
antibodi
respons
ebola
vaccin
contain
transcript
data
inde
solubl
factor
addit
surfac
marker
found
monocyt
dc
nk
cell
identifi
flow
cytometri
result
regard
involv
earli
signatur
consist
analyz
gene
express
level
instead
solubl
phenotyp
marker
transcript
profil
analysi
obtain
rna
sequenc
rnaseq
ebola
vaccin
trial
allow
comprehens
system
vaccinolog
approach
studi
ebola
candid
vaccin
rvsvzebov
anticip
licensur
year
indepth
character
immun
respons
present
earli
frequent
sampl
usual
also
limit
feasibl
rel
small
number
sampl
particip
extern
valid
dataset
avail
small
sampl
size
inher
phase
trial
allow
split
data
test
valid
set
howev
perform
statist
crossvalid
bootstrap
standard
approach
assess
predict
capac
model
context
small
sampl
size
conclus
system
vaccinolog
approach
comprehens
analyz
highdimension
innat
immun
marker
allow
identif
two
uniqu
innat
immun
signatur
correl
antibodi
induct
follow
vaccin
viral
vector
vaccin
rvsvzebov
find
support
effort
investig
role
enhanc
vaccin
immunogen
togeth
studi
confirm
immun
correl
protect
ebola
viru
diseas
could
ultim
lead
futur
studi
test
adjuv
prophylact
vaccin
flow
cytometri
analysi
pbmc
day
obtain
ficollhypaqu
densiti
gradient
centrifug
whole
blood
time
plasma
collect
particip
cytokinechemokin
analysi
state
otherwis
antibodi
purchas
biolegend
clone
state
within
parenthesi
dead
cell
identifi
exclud
analysi
stain
sampl
livedead
zombi
aqua
dye
biolegend
data
analyz
use
flow
jo
gate
strategi
nk
cell
dc
monocyt
see
figur
investig
blind
dose
group
time
point
p
valu
adjust
multipl
test
benjaminihochberg
procedur
plasma
sampl
vaccine
investig
collect
day
vaccin
store
c
prior
analysi
assay
perform
biorad
consist
ifng
tnfa
addit
ifna
tnfb
make
assay
sampl
read
duplic
accord
manufactur
protocol
bioplex
biorad
analyz
use
bioplex
manag
softwar
whole
blood
particip
directli
collect
paxgen
rna
tube
preanalytix
qiagen
day
vaccin
blood
collect
tube
invert
mix
immedi
collect
store
room
temperatur
storag
c
indic
manufactur
protocol
rna
isol
thaw
sampl
perform
accord
manufactur
direct
paxgen
blood
rna
kit
handbook
version
use
paxgen
blood
rna
kit
preanalytix
qiagen
includ
option
dnase
digest
step
extract
rna
sampl
store
c
total
rna
mrna
extract
use
nebnext
poli
mrna
magnet
isol
modul
new
england
biolab
rnaseq
librari
gener
use
nebnext
ultra
rna
librari
prep
kit
illumina
neb
accord
manufactur
recommend
size
qualiti
librari
visual
bioanalyz
highsensit
chip
agil
technolog
concentr
determin
qubit
fluoromet
life
technolog
dilut
librari
multiplexsequenc
illumina
hiseq
instrument
singl
read
run
sampl
rna
integr
number
rin
insuffici
librari
concentr
sequenc
depth
million
read
exclud
analys
among
includ
sampl
median
sequenc
depth
million
read
interquartil
rang
million
qualiti
control
rnaseq
raw
data
perform
fastqc
visual
softwar
read
align
human
refer
assembl
use
star
option
quantmod
genecount
appli
estim
read
per
gene
simultan
gener
count
data
read
map
exon
attribut
given
gene
count
done
gene
level
isoform
splice
variant
focu
studi
multimapp
exclud
count
gene
annot
obtain
ensembl
releas
http
wwwensemblorg
sampl
size
phase
nonrandom
openlabel
dose
escal
studi
n
trial
particip
per
dose
group
design
assess
major
safeti
risk
primari
endpoint
result
publish
previous
agnandji
et
al
present
ancillari
studi
use
sampl
trial
particip
two
report
dose
group
assess
earli
correl
antibodi
respons
pool
dose
group
object
assess
whether
earli
innat
immun
signatur
would
correl
later
antibodi
respons
regardless
dose
level
receiv
sampl
size
small
allow
stratifi
analys
moreov
individu
distribut
level
antibodi
level
indic
although
dose
effect
visibl
respons
level
overlap
group
statist
test
twosid
wilcoxon
signedrank
test
result
correct
test
multipl
use
adapt
fdr
method
benjamini
hochberg
tifa
trafinteract
protein
forkheadassoci
domain
nfkb
subunit
nfkb
subunit
chuk
conserv
helixloophelix
ubiquit
kinas
ikbkb
inhibitor
nfkb
kinas
subunit
beta
ikbk
inhibitor
nfkb
kinas
subunit
epsilon
ikbkg
inhibitor
nfkb
kinas
subunit
gamma
tnf
receptor
superfamili
member
tnf
receptorassoci
factor
cxc
motif
chemokin
ligand
plasma
cytokin
concentr
ikk
complex
k
b
kinas
complex
nfkb
complex
nuclear
factor
kb
complex
see
also
figur
approach
togeth
variabl
select
regress
method
thu
suit
analysi
highdimension
dataset
highli
correl
explanatori
variabl
innat
immun
respons
variabl
leverag
multivari
outcom
name
ebovkikwitspecif
gp
antibodi
level
day
ebovgueckedouspecif
gp
antibodi
level
day
take
account
withinsubject
correl
final
spl
model
select
crossvalid
mean
squar
error
predict
msep
proport
explain
varianc
wherea
final
multivari
linear
regress
model
select
use
crossvalid
rsr
well
goodnessoffit
criterion
adjust
coeffici
determin
r
variabl
center
reduc
spl
analys
wherea
origin
variabl
use
multivari
linear
model
interpret
biolog
measur
unit
miss
valu
imput
among
four
cell
popul
final
select
spl
concern
one
particip
analys
differenti
gene
express
vaccin
includ
avail
rnaseq
data
sampl
particip
use
voomlimma
pipelin
law
et
al
test
null
hypothesi
fold
chang
compar
day
gene
multiplicityadjust
p
use
fdr
control
benjamini
hochberg
consid
statist
signific
integr
analys
assess
earli
gene
express
correl
later
antibodi
respons
use
normal
gene
express
level
day
predictor
variabl
gene
mean
raw
count
per
time
point
includ
analys
particip
intermitt
miss
rnaseq
sampl
ie
time
point
miss
includ
analys
miss
rnaseq
data
imput
use
matrix
complet
packag
softimput
mazumd
et
al
spl
model
use
downselect
predictor
gene
correl
multivari
antibodi
respons
measur
similar
cytokin
cell
popul
integr
analys
robust
select
assess
bootstrap
statist
analys
perform
r
softwar
version
r
foundat
vienna
austria
pathway
analys
perform
ingenu
pathway
analysi
softwar
version
qiagen
addit
detail
regard
experiment
procedur
shown
supplement
experiment
procedur
trial
particip
gave
inform
consent
clinic
trial
protocol
receiv
ethic
approv
ethikkommiss
rztekamm
hamburg
ethic
committe
regulatori
clearanc
compet
author
paul
ehrlich
institut
written
inform
consent
receiv
particip
prior
inclus
studi
clinicaltrialsgov
two
group
trial
particip
includ
male
femal
particip
age
year
access
number
rnaseq
data
report
paper
ncbi
geo
supplement
inform
includ
supplement
experiment
procedur
six
figur
four
tabl
found
articl
onlin
http
work
present
carri
collabor
author
mma
rt
made
substanti
contribut
concept
design
interpret
data
particip
critic
revis
manuscript
import
intellectu
content
ar
lr
hl
made
substanti
contribut
concept
design
analysi
interpret
data
ar
lr
draft
manuscript
ar
also
particip
acquisit
data
gm
bph
cd
rk
hc
mez
vk
sb
made
substanti
contribut
concept
design
acquisit
data
particip
critic
revis
manuscript
import
intellectu
content
awl
vebcon
consortium
made
substanti
contribut
concept
design
particip
critic
revis
manuscript
import
intellectu
content
author
read
gave
final
approv
version
submit
revis
version
